 |
|
|
|
|
|
| |
 |
 |
|
|
 |
 |
|
 |
Ulrich von Andrian, M.D., Ph.D., Harvard Medical School
Dr. von Andrian is the Mallinckrodt Professor of Immunopathology and member of the Immune Disease Institute at the Harvard Medical School. Dr. von Andrian is an expert in leukocyte trafficking, T-cell homing and migration, extravasation and is world renown for the application of intravital microsopy to study the molecular mechanisms of interactions between blood cells and the vascular wall in living organisms. Dr. von Andrian received his M.D. and Ph.D. from Ludwig-Maximilians University in Munich, Germany. He did postdoctoral work at the La Jolla Institute for Experimental Medicine in California. He is a member of the European Academy of Sciences and the American Society for Cell Biology. In 2004, he was awarded the Amgen Outstanding Investigator Award.
|
|
Nicolas A. F. Chronos, M. D., Saint Joseph's Research Institute
Nicolas Chronos, M.D. is the Chief Medical and Scientific Officer of the American Cardiovascular Research Institute (ACRI) and the Saint Joseph's Research Institute in Atlanta. Dr. Chronos currently oversees approximately 60 preclinical trials at ACRI and 30 clinical trials at the Saint Joseph's Research Institute. Dr. Chronos is a practicing interventional cardiologist and is an Adjunct Professor of Cardiology and Medicine at Duke University.
|
 |
Jason Cyster, Ph.D., University of California, San Francisco
Dr. Cyster is a Professor in the Department of Microbiology and Immunology and an Investigator with the Howard Hughes Medical Institute at UCSF. His primary research interests are focused on defining molecular cues that guide leukocyte migration into secondary lymphoid organs. He is also examining self-tolerance mechanisms promoting autoreactive B cell elimination within lymphoid organs. |
 |
Roger M. Freidinger, Ph.D., Medicinal Chemistry Consultant
Dr. Freidinger retired from Merck Research Laboratories in 2005 after a 30 year career. He was most recently Executive Director, Medicinal Chemistry. His research activities have focused on the chemistry and medicinal chemistry of peptides, peptidomimetics, small molecule ligands for receptors, and enzyme inhibitors encompassing several therapeutic areas. Honors have included the Vincent du Vigneaud Award, Fellow of the American Association for the Advancement of Science, and the American Chemical Society Ralph Hirschmann Award in Peptide Chemistry. Dr. Freidinger was President of the American Peptide Society from 2003 - 2005. He was a member of the NIH Bio-organic and Natural Products Chemistry Study Section and several other advisory boards. |
 |
Michael Hanley, Ph.D., Amylin Pharmaceuticals, Chair of the Scientific Advisory Board
Dr. Hanley is the Vice President of Discovery Research at Amylin Pharmaceuticals. He was a Senior Consultant for Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron Corporation. Prior to that he held faculty positions at the Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis. Dr. Hanley has served on advisory or review panels for the NIH, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. He has set-up and directed research programs in several privately-held biotechnology companies, including Chemocentryx, PsychoGenics, and most recently Harvard-based Resolvyx Pharmaceuticals. |
 |
Alisa E. Koch, University of Michigan Medical School
Dr. Koch is the Frederick G. L. Huetwell and William D. Robinson Professor of Rheumatology at the University of Michigan Medical School. Her laboratory examines the immunopathogenesis of rheumatoid arthritis, with an emphasis on studying the role of monocytes, macrophages and vascular endothelial cells in this disease. Dr. Koch has a particular interest in the role of cellular adhesion and cytokines in the disease and has extensively studied the role of chemotaxis in immune cell migration into the arthritic joint. She is a graduate of Northwestern University's Six Year Honors Program in Medical Education (Chicago, IL) and did her residency at Loyola University (Maywood, IL) in Internal Medicine. She completed a fellowship in Rheumatology at Northwestern University. She is a member of the Association of American Physicians, a past President of the American Federation for Clinical Research, Midwest Chapter, and a member of the American College of Rheumatology. She has served as an Editor or been on the Editorial Board of a number of journals, including a recent co-editorship of Arthritis and Rheumatism. She is the author of 178 peer reviewed journal articles, a number of book chapters, and has edited a book on Chemokines in Disease. She is considered a thought leader in the area of rheumatoid arthritis. |
 |
David Scheinberg, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
Dr. Scheinberg is the Chairman of the Program in Molecular Pharmacology and Chemistry at the Memorial Sloan-Kettering Cancer Center in New York City. His research program is developing novel, targeted immunotherapies which attempt to exploit effectors and suppressors in the immune system. He is a thought leader in the area of hematological malignancies and radio-immunotherapy and was Chief of Memorial's Leukemia Service between 1992 and 2003. | |
|
 |
|
 |
|
|
|
